injectable glp 1 agonists Diabetes Patients Also Struggle to Access GLP-1 glp-1_analogs [TUSOM | Pharmwiki]

38.Jastreboff A

Given the prominent role of IL-17driven inflammation in obese PsA patients, GLP-1RAs may also enhance the efficacy of biologic agents targeting these pathways

Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in alzheimers disease

Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial

[DOI] [PubMed] [Google Scholar] 229.Yun S.P., Kam T.I., Panicker N., Kim S., Oh Y., Park J.S

In addition, the drug combination also had no effect on the intestinal microbiome in elderly patients with T2DM, but there was an increase in the percentage of bacteria of the genus Alistipes